Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease
Renal osteodystrophy is common in patients with chronic kidney disease and end-stage renal disease and leads to the risks of fracture and extraosseous vascular calcification. Secondary hyperparathyroidism (SHPT) is characterized by a compensatory increase in parathyroid hormone (PTH) secretion in re...
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
MDPI AG
2022-07-01
|
| Saila: | Pharmaceuticals |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/1424-8247/15/8/952 |